Effect of lacidipine and nifedipine GITS on platelet function in patients with essential hypertension.
With the aim of evaluating the effects on blood pressure, platelet function and insulin sensitivity of the dihydropiridines lacidipine and nifedipine GITS, a parallel double-blind study was carried out in a group of 20 patients with mild to moderate essential hypertension. They received a placebo for 4 weeks; then were divided at random into two groups of 10 patients each. Nifedipine GITS, 30 mg and lacidipine, 4 mg, were given during 16 weeks of active treatment. Blood pressure and heart rate were measured at the clinic in supine, sitting and standing positions, 24 +/- 1 h after the last dose. After the placebo and active phases were carried out, a platelet aggregation test was performed to determine platelet malondialdehyde production and a tolerance to 100 g of glucose by measuring glucaemia and plasma insulin. Both drugs reduced systolic and diastolic blood pressure at the same level, however there were observable differences in the rate of reduction. The nifedipine GITS reduced supine systolic blood pressure by 25 mm Hg in the first week, while the lacidipine did so by 11 mm Hg. At the end of the study period nifedipine reduced supine systolic blood pressure by 28 mm Hg and lacidipine by 20 mm Hg. Heart rate was increased slightly but significantly in the nifedipine GITS group only in the standing position. Both drugs reduced platelet aggregation ex vivo only marginally but they modified the malondialdehyde production, indicating an action on the arachidonic acid metabolic pathway.
Armas-Padilla
M C
MC
Clinical Pharmacology Unit, School of Medicine, Universidad Centroccidental Lisandro Alvarado, Barquisimeto, Venezuela.
Armas-Hernández
M J
MJ
Hernández-Hernández
R
R
Velasco
M
M
Pacheco
B
B
Carvajal
A R
AR
Castillo-Moreno
A
A
D016718:Arachidonic Acid / Q000378:metabolism; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D015220:Calcium Channels / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects*; D011187:Posture / Q000502:physiology; D016037:Single-Blind Method
D015415:Biomarkers; D015220:Calcium Channels; D004095:Dihydropyridines; C060285:lacidipine; D016718:Arachidonic Acid; D008315:Malondialdehyde; D009543:Nifedipine